OM
PMVP icon

Opaleye Management’s PMV Pharmaceuticals PMVP Stock Holding History

Opaleye Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-475,000
Closed -$770K – 53
2024
Q2 		$770K Buy
475,000
+3,519
+0.7% +$6.35K 0.18% 46
2024
Q1 		$802K Buy
+471,481
New +$881K 0.17% 48

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management's PMVP Position: Q3 2024 in Review

Opaleye Management sold out of PMV Pharmaceuticals (PMVP) in Q3 2024, closing a stake of 475,000 shares — an estimated $770K sold.

Opaleye Management first reported a position in PMVP in Q1 2024 and held it in 2 quarters. The position peaked at $802K in Q1 2024. 74 funds tracked by Wall St. Rank hold PMVP as of Q3 2024.

  • Opaleye Management reported no remaining PMV Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Opaleye Management sold 475,000 PMV Pharmaceuticals shares in Q3 2024, an estimated $770K.
  • Opaleye Management first reported a position in PMV Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Opaleye Management's PMV Pharmaceuticals position peaked at $802K in Q1 2024.
  • 74 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2024.

Based on Opaleye Management's 13F filing for Q3 2024, filed 14 Nov 2024.